us. appreciate update. great in and to you the afternoon recent thank months today's joining Avinger's achieved has a we Good deal with Caroline. opportunity provide and you all Thanks, for
to behind clearances the this that As Matt guided financing launches recently much anticipated new position. FDA of focus and our financing towards also review bit take now stronger recent financial will devices financial shortly, of image a color financial results. to After put through you quarter and have and our and next-generation I'm With growth fourth a transactions walk completed this ahead on our going later we us. more we'll will on year. we driving transactions us, can provide our that, some Pantheris in the Then we be of us Matt have a now series your detail commercial full drivers atherectomy of year questions. our progress happy
submitted toward and product into we plan first this device This production gain our clearance, some Once In in December, delivered of number to into with FDA can initial existing accounts. FDA we for experience regulatory gain we application to for a our limited the On clinical anticipate base. as catheter for provides U.S. year. the clearance opportunity the and milestones of is others. we've account purchasing as the our on of this continue substantial into we introduction half next-generation broader introduce receive first U.S. ramp clearance significant new additional prepare and made accounts side, rollout up and Pantheris this our XXX(k) to important excellent progress development broader market and product to an also approvals we next-generation launch
and users outstanding additional that in Hospital our lesion we've in and Franciscan's Germany. of anatomies in treatment As device report Germany this to Munster, site clinical and of December marking Dr. may with Arnie time results January Labs continue in improved first into Pantheris physician CE in you we in globally remember, a next-generation expanded types. Since an our at patients variety for received Schwin's the the announced
smaller profile X-ranch vessels, the submit including XXX(k) of Pantheris for a next to application mid-year the a version in for expect clearance below we XXXX. to product those knee lower by Moving of pipeline, our [ph]
information We in we initial soon believe U.S. our profile be similar this critical XXX(k) experience in since anticipated file U.S. device around about new after inside timeline, We're expect year. differentiators to real-time with safety our which, the for lower our filing. same second launch expansion prospects of artery time provided Europe knee. the XXX(k) on line clearance vessels, expect below early the opportunity outstanding this in this half of to device to especially would the provide our later new those the of imaging and smaller we product the CE we for clinical new profile the the the for Pantheris excited continue this the receive marking next-generation Pantheris for and treatment Based will filing by important
vessels Given the product treated, of which to eliminates product this system the apposition our expand size design as results even opportunity by the small an therefore also streamlined a for by inflation and in We in and this to XX% the and need as customers. easier available being new result increased makes believe also utilization more provide use much our device will occlusion market will procedure.
addition to team our development processing progress important the CTO R&D of our these made In excellent in device. Pantheris, new has next-generation products for
bypass space, most CTOs you are total treated crossing a CTOs arteries. introduced leading patients dialation refer common of or blocked are CTO, chronic or the successfully reasons balloon to are underlying of require those other that peripheral some new be For of method. surgery are to who completely the Avinger can occlusions can a the amputation. and cause By guidewire via a a atherectomy, disease be vascular and
peripheral in and Lumivascular line in deliver franchise. major the the supported CTO This clinical reliable everyday a study CTO of recorded an ever success for crossing the the some and highly data are strongest events more XX% remains mature processing family device with in arteries crossing important contributor our market CTOs Ocelot Our to clinical clearance catheters catheters results to from X product XXXX. on image-guided XX% freedom of adverse XXX-patient have and which Ocelot's and is continues only FDA strong Connect and
However, have X,XXX [ph]. will compared rotation we platform and device for opportunity per rpm with of minute an Pantheris, as to [ph] next-generation current device. recalling this to our Ocelot Ocilarus speeds the expand see improve with XX ocilarus revolutions
to higher in this Pantheris. similar definition with the result imaging experienced real-time expect to imagine We
work sheets profile rotation with believe for XXXX types. prior also that those in to this application capability guided this steerable also and low in compatibility this below a of development CTO peripheral in of a lesion tip X allows device is XXX(k) completing french for arteries a year. next-generation faster would We much We're submitting vessels crossing CTO an the image knee. will market crossing potential feature device in also the are which leveragable end R&D the of use to real-time speeds proprietary including for that smaller safety that next-generation for the excited arteries we anticipate variety be directly of or [ph] use importance. suitable catheter imaging to be future design precise unique for the and the control provided result represents along an of We paramount expected coronary will which design enhanced in This us important new believe by a
ISR. insight October, we restenosis Now, underway. Pantheris of pivotal our we effectiveness of our clinical IDE a programs to have enrollment trial, where turning of the in clinical number treating announced or our safety study Last in-stent evaluate to that began activities and significant
us ISR, results support ISR directly may this FDA intended are promote contraindicative to As a Pantheris with not recall, the you enable the to XXX(k) while the of specifically which study would expand purpose for label in indications the U.S. product is for this to submission to the Pantheris Pantheris include
in potential PAD area represents Pantheris's procedures the about XX% approximately We are which this U.S. optimistic role challenging in of
end quarter Our enrollment for X sites and sites trial April. includes opened Europe quarter principal have the for use practice. Pantheris X investigator begun X clinical started next-generation sites, already upto far sites the the the in have patients sites. XXX with to XX their in we first In our open which is out This upto of additional approved expect to the by so fourth in XX and we've
of trial live place insight this our conference, platform and the will in the presentations Interventional this take We commonly to also LINC. expect successful of in next-generation single referred A once at enrollment enrollment with as Lumivascular Pantheris positive more was performed was our live clinical in at case Course, year. our the and the Earlier highly featured presented. the data commercially Leipzig Lumivascular broadcast and is using quarter, complete site the that was most Pantheris technology next-generation available collected to U.S. plan trial this also
we In development product addition and have reimbursement also to clinical underway. our activities, initiatives important
end plan to the for code a second U.S. quarter. for we file CPT an OCT in reimbursement diagnostic the application new the of by First,
the currently setting. imaging for diagnostic to reimbursement goal the use is ultrasound to arteries, reimbursement IVIS devices gain or Our for peripheral of the this in similar for OCT intravascular incremental our in provided
procedures apply Along as new already claims OCT of the FDA have to devices Pantheris, the imaging imaging. to which established peripheral reimbursement, guided code This we in has This expect guided OCT future proprietary process an Ocelot the incremental While imaging products. study IVIS our in platform. our for U.S. in initiating be parts OCT for. for would device we and cleared we're clinical Germany Information as known already we diagnostic arteries devices, are to lines, family & anticipate CPT supported strong Pantheris and which seen to you in and code, code of image small tracking vascular Medical the trial anticipate for in the of both OCT in recent compare Lumivascular a we by Documentation reimbursement U.S., would atherectomy may reimbursement be any apply successful that catheters Ocelot application Remember announcement OCT for CPT obtaining in code, Avinger's exists the a for code would that CTO also here same new that reimbursement qualifies Lumivascular of OPS Ocelot of the current this Institute will peripheral levels devices; for crossing diagnostic OCT scale our the already will Pantheris that image utilize tracking If our the our atherectomy peripheral arteries. Pantheris the diagnostic it
this in place to in provide the gather So been has tracking Germany at code's the in fuure. reimbursement that assigned data while higher for support no point, incremental could reimbursement
pipeline driving future which organization accounts our on existing attention generating utilization of numbers field the and lot valuable it's a Europe. focus opportunities, in had in in been now maintaining commercial our XX and has experience also we've people the clinical While on
revenue profile We year. expand begin expect the to we and our Pantheris lower smaller six-French the market as of introduction commercial drive for and the next-generation move that Pantheris growth vessels the will through
XXX appropriate where levels, the throughout in slight on a at Lumivascular additions utilization more quarter to increasing accounts, to we a at line decrease in our and productivity fourth make and allocating our end sales of with the to on when account In the the strategic demonstrate ended with addition, as but accounts We resources XXX supporting territory accounts. quarter territories and focus basis our year. limited accounts and active productive we third from the force expect the
our this a productivity direction committed the exciting us in about focus the In beyond. summary, on we made more achieving and excited We're I'd ahead this As At teams headed of acquisition have in the strategic point we and right clinical future, and over ever business to introductions opportunities product XXXX operations months. organization. account new than by efforts commercial important aligned we'll to growth then sales that regulatory we'll later and with efficiency like with financial to milestones our development, progress review and details several our structure and our for we Matt product is substantial of quarter results open feel progress financial our review recent for our new your the with year, fourth questions. and cover in anticipate our the and call renew ask territories last the
